MedTrace Logo

Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)

NCT05620628 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-01-21

No results posted yet for this study

Summary

For patients who failed primary chemotherapy with MET amplification, The efficacy and safety of the chemotherapy are evaluated by using dervalumab and saboritinib in combination.

Conditions

  • Stomach Cancer, Adenocarcinoma

Interventions

DRUG

Durvalumab

Durvalumab will be administered at 1500mg every 4 weeks from cycles 1 day 1.

DRUG

Savolitinib

Savoritinib 600mg will be administered orally a day for 28 days as one cycle.

Sponsors & Collaborators

  • Jeeyun Lee

    lead OTHER

Principal Investigators

  • Jeeyun lee, Ph,MD · Samsung Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-05
Primary Completion
2026-12-31
Completion
2027-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05620628 on ClinicalTrials.gov